Lorenzo Gaetani

TL;DR: Evidence that both CSF and blood NfL may serve as diagnostic, prognostic and monitoring biomarkers in neurological diseases is progressively increasing, and N fL is one of the most promising biomarkers to be used in clinical and research setting in the next future.

TL;DR: Evidence suggests potential diagnostic and prognostic value of CSF and blood biomarkers closely reflecting the pathophysiology of Parkinson's disease, such as α-synuclein species, lysosomal enzymes, markers of amyloid and tau pathology, and neurofilament light chain.

TL;DR: CSF NfL is confirmed to be a reliable marker in AD and MS, and a disease-severity marker in MS patients, as well as other neurological noninflammatory and non-neurodegenerative diseases.

TL;DR: It is found that N-acetylserotonin (NAS), a tryptophan metabolite produced along the serotonin pathway, acts as a positive allosteric modulator (PAM) of IDO1 and thus increases kynurenine-mediated AhR activation in DCs and may set the basis for the development ofIDO1 PAMs as first-in-class drugs in autoimmune/neuroinflammatory diseases.

TL;DR: The benefits of using fluid biomarkers for patient stratification, target engagement, and outcome assessment, as well as the most recent developments in neuroinflammatory and neurodegenerative diseases are discussed.